论文部分内容阅读
目的评价自体细胞因子诱导的杀伤细胞(CIK细胞)联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法59例患者分成A组(自体CIK细胞联合TP方案化疗29例)与B组(单用TP方案化疗30例)。对两组的生活质量、免疫学反应、缓解率(RR)、疾病进展时间(TTP)与生存期进行观察比较。CIK细胞由自体外周血单个核细胞诱导产生。结果CIK细胞的数量与杀伤活性均在培养第14￣21天达到高峰。与B组相比,A组患者的免疫力与生活质量、疾病控制率(DCR)显著提高,中位生存时间(MST)明显延长,TTP与总生存期(OS)均明显延长,差异均有统计学意义(均P<0.05)。两组间RR差异无统计学意义(P>0.05)。结论自体CIK细胞回输安全、副作用小。CIK细胞联合化疗治疗晚期NSCLC能有效改善患者生活质量,并能延长生存期。
Objective To evaluate the clinical efficacy of autologous cytokine-induced killer (CIK) cells combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 59 patients were divided into group A (autologous CIK cells with TP chemotherapy in 29 cases) and group B (TP chemotherapy alone in 30 cases). The quality of life, immunological response, RR, TTP and survival of the two groups were observed and compared. CIK cells are induced by autologous peripheral blood mononuclear cells. Results The number of CIK cells and cytotoxic activity all reached the peak on the 14th to 21st days of culture. Compared with group B, the immunity, quality of life and disease control rate (DCR) in group A were significantly increased, the median survival time (MST) was significantly prolonged, TTP and total survival (OS) were significantly longer, the differences were Statistical significance (all P <0.05). There was no significant difference in RR between the two groups (P> 0.05). Conclusions Autologous CIK cells are safe for transfusion with few side effects. CIK cells combined with chemotherapy for advanced NSCLC can effectively improve the quality of life of patients, and can prolong survival.